ArticleTurkish journal of biology = Turk biyoloji dergisi2025
Royal jelly with ellagic acid inhibits the glycolytic pathway and induces apoptosis through multiple pathways in colorectal cancer.
Article in Turkish journal of biology = Turk biyoloji dergisi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Developing novel chemotherapeutics with high anticancer efficacy and low toxicity remains a critical challenge in oncology. Natural products have shown promise due to their multitargeted activity and favorable safety profiles. The present study investigates the combined anticancer effects of royal jelly (RJ) and ellagic acid (EA), two potent antioxidants of animal and plant origin. Materials and methods: Royal jelly (RJ) and ellagic acid (EA) were applied to HT29 (ATCC HTB-38, Human colorectal adenocarcinoma), HCT116 (ATCC CCL-247, Human colorectal carcinoma) and BEAS-2B (ATCC CRL-3588, human bronchial epithelium) cell lines, and their antiproliferative effects were evaluated using a xCELLigence Real-Time Cell Analyzer (RTCA MP). The effect of the combination of RJ and EA on the glycolytic pathway was determined using a Seahorse XFe24 Analyzer, and the apoptotic process was evaluated by DNA laddering and the expression of the Results: RJ with EA, when used in combination, significantly reduced the extracellular acidification rate (ECAR), effectively inhibiting aerobic glycolysis, especially in HCT116, and induced apoptosis in HCT116 and HT29 cells by increasing the Conclusion: RJ with EA used in combination demonstrates potent anticancer effects in colorectal cancer by suppressing glycolysis and activating apoptosis, with apparent therapeutic potential as a novel cancer treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.